What is a stock summary page? Click here for an overview.
Business Description
IDEAYA Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US45166A1025
Compare
Compare
Traded in other countries / regions
IDYA.USA30J.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-05-23Description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.28 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 10.92 | |||||
| Beneish M-Score | -3.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.3 | |||||
| 3-Year EBITDA Growth Rate | -43.5 | |||||
| 3-Year EPS without NRI Growth Rate | -33.6 | |||||
| 3-Year FCF Growth Rate | -22.9 | |||||
| 3-Year Book Growth Rate | 16.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 195.86 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.96 | |||||
| 9-Day RSI | 33.01 | |||||
| 14-Day RSI | 33.41 | |||||
| 3-1 Month Momentum % | -26.42 | |||||
| 6-1 Month Momentum % | -34.6 | |||||
| 12-1 Month Momentum % | -54.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.97 | |||||
| Quick Ratio | 14.97 | |||||
| Cash Ratio | 14.68 | |||||
| Days Sales Outstanding | 0.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.9 | |||||
| Shareholder Yield % | -51.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4671.07 | |||||
| Net Margin % | -3942.31 | |||||
| FCF Margin % | -3592.01 | |||||
| ROE % | -29.19 | |||||
| ROA % | -27.88 | |||||
| ROIC % | -118.88 | |||||
| 3-Year ROIIC % | -101.14 | |||||
| ROC (Joel Greenblatt) % | -2046.48 | |||||
| ROCE % | -34.28 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 183.89 | |||||
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.2 | |||||
| EV-to-EBIT | -2.16 | |||||
| EV-to-Forward-EBIT | -2.55 | |||||
| EV-to-EBITDA | -2.18 | |||||
| EV-to-Forward-EBITDA | -2.58 | |||||
| EV-to-Revenue | 100.83 | |||||
| EV-to-Forward-Revenue | 28.64 | |||||
| EV-to-FCF | -2.81 | |||||
| Price-to-GF-Value | 7.91 | |||||
| Price-to-Projected-FCF | 18.62 | |||||
| Price-to-Net-Current-Asset-Value | 2.04 | |||||
| Price-to-Net-Cash | 2.08 | |||||
| Earnings Yield (Greenblatt) % | -46.3 | |||||
| FCF Yield % | -19.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IDYA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IDEAYA Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7 | ||
| EPS (TTM) ($) | -3.3 | ||
| Beta | -0.04 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 0.84 | ||
| Volatility % | 38.38 | ||
| 14-Day RSI | 33.41 | ||
| 14-Day ATR ($) | 1.147387 | ||
| 20-Day SMA ($) | 17.744 | ||
| 12-1 Month Momentum % | -54.61 | ||
| 52-Week Range ($) | 14.395 - 44.42 | ||
| Shares Outstanding (Mil) | 87.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDEAYA Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDEAYA Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
IDEAYA Biosciences Inc Frequently Asked Questions
What is IDEAYA Biosciences Inc(IDYA)'s stock price today?
The current price of IDYA is $14.70. The 52 week high of IDYA is $44.42 and 52 week low is $14.40.
When is next earnings date of IDEAYA Biosciences Inc(IDYA)?
The next earnings date of IDEAYA Biosciences Inc(IDYA) is 2025-05-07 Est..
Does IDEAYA Biosciences Inc(IDYA) pay dividends? If so, how much?
IDEAYA Biosciences Inc(IDYA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers